New cholesterol drug AD-117: does food change how it works?

NCT ID NCT07495514

Completed Knowledge-focused Sponsor: Addpharma Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new drug called AD-117, which is being developed for mixed dyslipidemia (abnormal cholesterol levels). The study will give a single dose to 60 healthy adults, either with or without food, to see how food changes the drug's levels in the blood and its safety. The results will help decide how to take the drug in future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AD-117
What this could lead to: If successful, this study will show whether AD-117 should be taken with or without food, helping to design future trials for treating mixed dyslipidemia.
What could go wrong: This is a very early phase 1 study in healthy volunteers, not patients. It only measures drug levels and safety, not whether the drug actually works for the condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOOD EFFECT STUDY OF AD-117 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperlipidemia, familial combined, LPL related

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOOD EFFECT STUDY OF AD-117 MIXED DYSLIPIDEMIA

Contacts and locations

Locations

H PLUS YANGJI HOSPITAL, Seoul,

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.